- Home
- LVTX
as 10-08-2025 4:00pm EST
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
| Founded: | 2016 | Country: | Netherlands |
| Employees: | N/A | City: | UTRECHT |
| Market Cap: | 40.8M | IPO Year: | 2021 |
| Target Price: | $1.58 | AVG Volume (30 days): | 437.0K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $2.09 | Next Earning Date: | 08-13-2025 |
| Revenue: | $4,990,000 | Revenue Growth: | -32.55% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of LAVA Therapeutics N.V. (LVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 19 '25 | Sell | $1.40 | 2,903,403 | $4,068,828.96 | 0 | |
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 18 '25 | Sell | $1.44 | 594,902 | $857,729.70 | 0 | |
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 17 '25 | Sell | $1.49 | 589,532 | $877,931.05 | 0 | |
| Versant Venture Capital VI, L.P. | LVTX | 10% Owner | Sep 16 '25 | Sell | $1.53 | 500,000 | $766,600.00 | 0 |
Latest LAVA Therapeutics N.V. News
LVTX Breaking Stock News: Dive into LVTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 months ago
Here's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn Situation
GlobeNewswire
5 months ago
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
GlobeNewswire
6 months ago
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
GlobeNewswire
6 months ago
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
7 months ago
LAVA Announces Evaluation of Strategic Options
GlobeNewswire
9 months ago
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
GlobeNewswire
10 months ago
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
GlobeNewswire
a year ago
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Compare LVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LVTX LAVA Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.